NewcelX Ltd. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: —
EBITDA: +75.3%
EBIT: +62.4%
EPS: —
Free cash flow: +70.0%
Operating cash flow: +70.0%

Forward estimates

Revenue: —
EBITDA: —
EPS: —

Three-year CAGR

Revenue: —
EBITDA: +38.4%
EBIT: +43.5%
Net income: —
EPS: +91.8%
Free cash flow: +35.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.